Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial.
Steg PG, Bhatt DL, James SK, Darlington O, Hoskin L, Simon T, Fox KM, Leiter LA, Mehta SR, Harrington RA, Himmelmann A, Ridderstråle W, Andersson M, Bueno H, De Luca L, Tank A, Mellström C, McEwan P. Steg PG, et al. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 2;8(8):777-785. doi: 10.1093/ehjcvp/pvac032. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 35488865 Free PMC article. Clinical Trial.
Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry).
Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CP; REACH Registry Investigators. Steinberg BA, et al. Among authors: steg pg. Am J Cardiol. 2007 May 1;99(9):1212-5. doi: 10.1016/j.amjcard.2006.12.039. Epub 2007 Mar 16. Am J Cardiol. 2007. PMID: 17478144
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH, Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ; CHARISMA Investigators. Wang TH, et al. Among authors: steg pg. Eur Heart J. 2007 Sep;28(18):2200-7. doi: 10.1093/eurheartj/ehm274. Epub 2007 Aug 2. Eur Heart J. 2007. PMID: 17673448 Clinical Trial.
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, Hamm C, Hu T, Fox KA, Topol EJ; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Eikelboom JW, et al. Among authors: steg pg. Circulation. 2008 Oct 21;118(17):1705-12. doi: 10.1161/CIRCULATIONAHA.108.768283. Epub 2008 Oct 6. Circulation. 2008. PMID: 18838564 Clinical Trial.
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG, Avezum A, Afzal R, Piegas LS, Faxon DP, Widimsky P, Budaj A, Chrolavicius S, Rupprecht HJ, Jolly S, Granger CB, Fox KA, Bassand JP, Yusuf S; OASIS 5 and 6 Investigators. Mehta SR, et al. Among authors: steg pg. Circulation. 2008 Nov 11;118(20):2038-46. doi: 10.1161/CIRCULATIONAHA.108.789479. Epub 2008 Oct 27. Circulation. 2008. PMID: 18955665 Clinical Trial.
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S; CURRENT-OASIS 7 Steering Committee. Mehta SR, et al. Am Heart J. 2008 Dec;156(6):1080-1088.e1. doi: 10.1016/j.ahj.2008.07.026. Epub 2008 Nov 1. Am Heart J. 2008. PMID: 19033002 Clinical Trial.
Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry.
Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liau CS, Goto S, Röther J, Steg PG, Hirsch AT; REACH Registry Investigators. Cacoub PP, et al. Among authors: steg pg. Atherosclerosis. 2009 Jun;204(2):e86-92. doi: 10.1016/j.atherosclerosis.2008.10.023. Epub 2008 Oct 31. Atherosclerosis. 2009. PMID: 19054514
Patients with peripheral arterial disease in the CHARISMA trial.
Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA; CHARISMA Investigators. Cacoub PP, et al. Among authors: steg pg. Eur Heart J. 2009 Jan;30(2):192-201. doi: 10.1093/eurheartj/ehn534. Epub 2009 Jan 9. Eur Heart J. 2009. PMID: 19136484 Clinical Trial.
Early versus delayed, provisional eptifibatide in acute coronary syndromes.
Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators. Giugliano RP, et al. N Engl J Med. 2009 May 21;360(21):2176-90. doi: 10.1056/NEJMoa0901316. Epub 2009 Mar 30. N Engl J Med. 2009. PMID: 19332455 Free article. Clinical Trial.
Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.
Sculpher MJ, Lozano-Ortega G, Sambrook J, Palmer S, Ormanidhi O, Bakhai A, Flather M, Steg PG, Mehta SR, Weintraub W. Sculpher MJ, et al. Among authors: steg pg. Am Heart J. 2009 May;157(5):845-52. doi: 10.1016/j.ahj.2009.02.017. Am Heart J. 2009. PMID: 19376310 Clinical Trial.
1,220 results